These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8308718)

  • 1. Estimation of absorption rate constant in a one-compartment model with the profile of the bioavailable dose eliminated as a function of multiples of half-life.
    Macheras P; Symillides M; Reppas C
    J Pharm Sci; 1993 Dec; 82(12):1298-300. PubMed ID: 8308718
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple-dose pharmacokinetics of a long half-life drug: contributions of mathematical modeling.
    Nedelman JR; Gibiansky E; Cramer J; Kovarik J; Meligeni J; Robbins B
    Eur J Drug Metab Pharmacokinet; 1997; 22(2):179-84. PubMed ID: 9248788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equations for the fraction of bioavailable dose remaining in the body in the one-compartment model.
    Macheras P; Symillides M; Reppas C
    Biopharm Drug Dispos; 1992 Apr; 13(3):229-32. PubMed ID: 1576330
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal sampling times in bioequivalence tests.
    Kong FH; Gonin R
    J Biopharm Stat; 2000 Feb; 10(1):31-44. PubMed ID: 10709799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cutoff time point of the partial area method for assessment of rate of absorption in bioequivalence studies.
    Macheras P; Symillides M; Reppas C
    Pharm Res; 1994 Jun; 11(6):831-4. PubMed ID: 7937521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the assessment of the relative magnitude of rate constants in the linear open one-compartment model.
    Macheras P; Symillides M; Reppas C
    J Pharm Sci; 1992 Dec; 81(12):1231-3. PubMed ID: 1491348
    [No Abstract]   [Full Text] [Related]  

  • 7. Estimation of drug excretion rate from blood into the gut using a three-compartment closed model.
    Wu G
    Pharmacol Res; 1998 Feb; 37(2):157-63. PubMed ID: 9572072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compartmental mean residence time in a mammillary model with an effect compartment after intravenous or oral administration.
    Plusquellec Y; Houin G
    J Biomed Eng; 1990 Nov; 12(6):523-6. PubMed ID: 2266749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of carbamazepine. Part I: A new bioequivalency parameter based on a relative bioavailability trial.
    Kayali A; Tuğlular I; Ertaş M
    Eur J Drug Metab Pharmacokinet; 1994; 19(4):319-25. PubMed ID: 7737233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic model of human insulin following different routes of administration.
    Potocka E; Baughman RA; Derendorf H
    J Clin Pharmacol; 2011 Jul; 51(7):1015-24. PubMed ID: 20940337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of methods for estimating the rate constant of a one-compartment absorption model when absorption and elimination rate constants are equal.
    Hoke JF; Ravis WR
    J Pharm Sci; 1992 Apr; 81(4):401-2. PubMed ID: 1501081
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of compounding on bioavailability.
    Riviere JE
    J Am Vet Med Assoc; 1994 Jul; 205(2):226-31. PubMed ID: 7928583
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel extravascular input function for the assessment of drug absorption in bioavailability studies.
    Weiss M
    Pharm Res; 1996 Oct; 13(10):1547-53. PubMed ID: 8899849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically relevant two-compartment pharmacokinetic models for skin.
    McCarley KD; Bunge AL
    J Pharm Sci; 2000 Sep; 89(9):1212-35. PubMed ID: 10944386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics and bioavailability of alizapride (author's transl)].
    Houin G; Bree F; Tillement JP
    Sem Hop; 1982 Feb; 58(6):339-44. PubMed ID: 6280299
    [No Abstract]   [Full Text] [Related]  

  • 16. Four compartment mammillary model applied to the pharmacokinetics of a spiroarsorane administered orally to rabbits.
    de Biasi J; Rekik L
    J Biomed Eng; 1991 Sep; 13(5):439-40. PubMed ID: 1795514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-based minibolus delivery as an alternative to continuous infusion for drugs that exhibit a biophase lag.
    Kern SE; Westenskow DR
    J Pharmacokinet Biopharm; 1997 Apr; 25(2):191-208. PubMed ID: 9408859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of direct search optimization for pharmacokinetic parameter estimation.
    Khorasheh F; Sattari S; Gerayeli A; Ahmadi AM
    J Pharm Pharm Sci; 1999; 2(3):92-8. PubMed ID: 10953255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of the analysis and interpretation of bioavailability studies in man.
    Wagner JG
    Arzneimittelforschung; 1976; 26(1A):105-8. PubMed ID: 947190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size determination for the two one-sided tests procedure in bioequivalence.
    Liu JP; Chow SC
    J Pharmacokinet Biopharm; 1992 Feb; 20(1):101-4. PubMed ID: 1588502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.